25.78

0.12% 0.03

After Hours: 25.78

Maze Therapeutics Inc (MAZE)

Overview News Price History Discussions Forecast

Maze Therapeutics Inc stock is traded at $25.78, with a volume of 405.27K. It is up +0.12% in the last 24 hours and down -2.72% over the past month. Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Previous Close:

$25.75

Open:

$25.8

24h Volume:

405.27K

Relative Volume:

0.49

Market Cap:

$1.43B

Revenue:

$2.50M

Net Income/Loss:

$-131.12M

P/E Ratio:

-9.0676

EPS:

-2.8431

Net Cash Flow:

$-112.73M

1W Performance:

+0.86%

1M Performance:

-2.72%

6M Performance:

-28.90%

1Y Performance:

+153.49%

1-Day Range:

$25.49

$26.09

1-Week Range:

$23.76

$26.09

52-Week Range:

$9.732

$53.65

Maze Therapeutics Inc Stock (MAZE) Company Profile

Name

Maze Therapeutics Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(650) 850-5070

Address

171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO

Employee

141

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

MAZE's Discussions on Twitter

Compare MAZE vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MAZE Maze Therapeutics Inc	25.78	1.43B	2.50M	-131.12M	-112.73M	-2.8431
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Buy
Mar-10-26	Initiated	Mizuho	Outperform
Dec-04-25	Initiated	Wells Fargo	Overweight
Nov-14-25	Initiated	Raymond James	Outperform
Sep-02-25	Initiated	BTIG Research	Buy
Jul-23-25	Initiated	H.C. Wainwright	Buy
Jul-08-25	Initiated	Wedbush	Outperform

View All

Maze Therapeutics Inc Stock (MAZE) Latest News

May 24, 2026

J.P. Morgan Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Cuts Target Price to $53 - Moomoo

May 24, 2026

May 23, 2026

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - AOL.com

May 23, 2026

Maze Therapeutics, Inc. Files Form 8-K with SEC: Company Details, Nasdaq Listing, and Contact Information - Minichart

May 23, 2026

May 19, 2026

100% Of This Maze Therapeutics Insider's Holdings Were Sold - 富途牛牛

May 19, 2026

Maze Therapeutics CEO Jason Coloma sells $50,388 in stock By Investing.com - Investing.com Australia

May 19, 2026

May 18, 2026

Maze Therapeutics Insider Sold Shares Worth $393,354, According to a Recent SEC Filing - Moomoo

May 18, 2026

Maze Therapeutics CEO Jason Coloma sells $50,388 in stock - Investing.com

May 18, 2026

CEO Coloma trusts trim 1,938 Maze Therapeutics (MAZE) shares under 10b5-1 plan - Stock Titan

May 18, 2026

Maze Therapeutics (MAZE) CMO sells 15,000 shares, exercises options - Stock Titan

May 18, 2026

May 17, 2026